A citation-based method for searching scientific literature

Stephen Tyring, Alice Gottlieb, Kim Papp, Ken Gordon, Craig Leonardi, Andrea Wang, Deepa Lalla, Michael Woolley, Angelika Jahreis, Ralph Zitnik, David Cella, Ranga Krishnan. Lancet 2006
Times Cited: 726







List of co-cited articles
1304 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Kim A Papp, Craig Leonardi, Alan Menter, Jean-Paul Ortonne, James G Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B Russell, Elizabeth H Z Thompson,[...]. N Engl J Med 2012
689
10

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
P C M van de Kerkhof, S Segaert, M Lahfa, T A Luger, Z Karolyi, A Kaszuba, G Leigheb, F M Camacho, D Forsea, C Zang,[...]. Br J Dermatol 2008
127
10

Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.
Hai-Zhen Yang, Ke Wang, Hong-Zhong Jin, Tian-Wen Gao, Sheng-Xiang Xiao, Jin-Hua Xu, Bao-Xi Wang, Fu-Ren Zhang, Chun-Yang Li, Xiao-Ming Liu,[...]. Chin Med J (Engl) 2012
42
23



Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
L Cai, J Gu, J Zheng, M Zheng, G Wang, L-Y Xi, F Hao, X-M Liu, Q-N Sun, Y Wang,[...]. J Eur Acad Dermatol Venereol 2017
45
22

Cytokine-associated emotional and cognitive disturbances in humans.
A Reichenberg, R Yirmiya, A Schuld, T Kraus, M Haack, A Morag, T Pollmächer. Arch Gen Psychiatry 2001
861
9


Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
Lucile Capuron, Jane F Gumnick, Dominique L Musselman, David H Lawson, Andrea Reemsnyder, Charles B Nemeroff, Andrew H Miller. Neuropsychopharmacology 2002
502
9

Inflammation and clinical response to treatment in depression: A meta-analysis.
R Strawbridge, D Arnone, A Danese, A Papadopoulos, A Herane Vives, A J Cleare. Eur Neuropsychopharmacol 2015
289
9

Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice.
J C O'Connor, M A Lawson, C André, M Moreau, J Lestage, N Castanon, K W Kelley, R Dantzer. Mol Psychiatry 2009
750
9

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
M Bryant Howren, Donald M Lamkin, Jerry Suls. Psychosom Med 2009
9

Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity.
Neil A Harrison, Lena Brydon, Cicely Walker, Marcus A Gray, Andrew Steptoe, Hugo D Critchley. Biol Psychiatry 2009
432
9


Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Rosa Parisi, Deborah P M Symmons, Christopher E M Griffiths, Darren M Ashcroft. J Invest Dermatol 2013
9

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi,[...]. J Dermatol Sci 2011
134
9

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
170
9

Inflammation in Depression and the Potential for Anti-Inflammatory Treatment.
Ole Kohler, Jesper Krogh, Ole Mors, Michael Eriksen Benros. Curr Neuropharmacol 2016
167
8

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
K Reich, F O Nestle, K Papp, J-P Ortonne, Y Wu, M Bala, R Evans, C Guzzo, S Li, L T Dooley,[...]. Br J Dermatol 2006
102
8

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
165
8


Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
240
8

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.
Michael E Benros, Berit L Waltoft, Merete Nordentoft, Søren D Ostergaard, William W Eaton, Jesper Krogh, Preben B Mortensen. JAMA Psychiatry 2013
267
8

Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.
Elaine Setiawan, Alan A Wilson, Romina Mizrahi, Pablo M Rusjan, Laura Miler, Grazyna Rajkowska, Ivonne Suridjan, James L Kennedy, P Vivien Rekkas, Sylvain Houle,[...]. JAMA Psychiatry 2015
409
8

Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Jerry Bagel, Charles Lynde, Stephen Tyring, Gregory Kricorian, Yifei Shi, Paul Klekotka. J Am Acad Dermatol 2012
68
11

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
98
8

Depression as a microglial disease.
Raz Yirmiya, Neta Rimmerman, Ronen Reshef. Trends Neurosci 2015
343
8

Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.
Rita Haapakoski, Julia Mathieu, Klaus P Ebmeier, Harri Alenius, Mika Kivimäki. Brain Behav Immun 2015
453
7

Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward.
Naomi I Eisenberger, Elliot T Berkman, Tristen K Inagaki, Lian T Rameson, Nehjla M Mashal, Michael R Irwin. Biol Psychiatry 2010
318
7

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G Krueger, Richard G Langley, Craig Leonardi, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Lisa T Dooley, Mark Lebwohl. N Engl J Med 2007
586
7

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.
Michael Maes, Raz Yirmyia, Jens Noraberg, Stefan Brene, Joe Hibbeln, Giulia Perini, Marta Kubera, Petr Bob, Bernard Lerer, Mario Maj. Metab Brain Dis 2009
554
7

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
S R Feldman, A B Gottlieb, M Bala, Y Wu, D Eisenberg, C Guzzo, S Li, L T Dooley, A Menter. Br J Dermatol 2008
61
11


Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
Shahin Akhondzadeh, Sara Jafari, Firoozeh Raisi, Abbas Ali Nasehi, Aboulfazl Ghoreishi, Bahman Salehi, Soodeh Mohebbi-Rasa, Maedeh Raznahan, Abbas Kamalipour. Depress Anxiety 2009
238
7

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Seyed-Hesameddin Abbasi, Fahimeh Hosseini, Amirhossein Modabbernia, Mandana Ashrafi, Shahin Akhondzadeh. J Affect Disord 2012
185
7


Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
K A Papp, R G Langley, B Sigurgeirsson, M Abe, D R Baker, P Konno, S Haemmerle, H J Thurston, C Papavassilis, H B Richards. Br J Dermatol 2013
258
7

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.
Wenjun Geng, Jianhua Zhao, Jixing Fu, Huamin Zhang, Shaohua Qiao. Exp Ther Med 2018
12
58

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.
Shanu Kohli Kurd, Andrea B Troxel, Paul Crits-Christoph, Joel M Gelfand. Arch Dermatol 2010
399
6

Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder.
Triin Eller, Veiko Vasar, Jakov Shlik, Eduard Maron. Prog Neuropsychopharmacol Biol Psychiatry 2008
207
6

Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Jian-Jun Yang, Nan Wang, Chun Yang, Jin-Yun Shi, Hai-Ying Yu, Kenji Hashimoto. Biol Psychiatry 2015
102
6

Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.
M Maes, C Song, A H Lin, S Bonaccorso, G Kenis, R De Jongh, E Bosmans, S Scharpé. Neuropsychopharmacology 1999
272
6

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Alan Menter, Alice Gottlieb, Steven R Feldman, Abby S Van Voorhees, Craig L Leonardi, Kenneth B Gordon, Mark Lebwohl, John Y M Koo, Craig A Elmets, Neil J Korman,[...]. J Am Acad Dermatol 2008
823
6

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
R Krishnan, D Cella, C Leonardi, K Papp, A B Gottlieb, M Dunn, C F Chiou, V Patel, A Jahreis. Br J Dermatol 2007
86
6


Immune system to brain signaling: neuropsychopharmacological implications.
Lucile Capuron, Andrew H Miller. Pharmacol Ther 2011
605
6

The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
P Persoons, S Vermeire, K Demyttenaere, B Fischler, J Vandenberghe, L Van Oudenhove, M Pierik, T Hlavaty, G Van Assche, M Noman,[...]. Aliment Pharmacol Ther 2005
153
6


Social stress induces neurovascular pathology promoting depression.
Caroline Menard, Madeline L Pfau, Georgia E Hodes, Veronika Kana, Victoria X Wang, Sylvain Bouchard, Aki Takahashi, Meghan E Flanigan, Hossein Aleyasin, Katherine B LeClair,[...]. Nat Neurosci 2017
262
6

Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis.
S P Leighton, L Nerurkar, R Krishnadas, C Johnman, G J Graham, J Cavanagh. Mol Psychiatry 2018
91
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.